Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances
(1997; 41 pages) View the PDF document
Table of Contents
Open this folder and view contents1. General introduction
Open this folder and view contents2. Elements in the INN system
Open this folder and view contents3. Principles for selection of INNs
View the document4. Protection of INNs
Open this folder and view contents5. How to apply for an INN
View the document6. References for supporting material
View the documentAnnex 1: Background information on the INN programme
View the documentAnnex 2: General principles for guidance in devising international nonproprietary names for pharmaceutical substances
View the documentAnnex 3: List of common stems used in the selection of INNs
View the documentAnnex 4: Specific groups of biological compounds
View the documentAnnex 5: WHA46.19 - Nonproprietary names for pharmaceutical substances
View the documentAnnex 6: Procedure for the selection of international nonproprietary names for pharmaceutical substances
View the documentAnnex 7: Applications for INNs through national authorities (addresses)
View the documentAnnex 8: INN request form
 

Annex 8: INN request form


WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTE

Request for an international nonproprietary name (INN)
Demande de dénomination commune internationale (DCI)

Authority or manufacturer
Autorité ou fabricant:

Name of applicant / nom du demandeur:
Name of responsible officer / nom du responsable:
Address / adresse:

Telephone No / No. de téléphone:
Fax No. / No. de fax

We hereby request the World Health Organization to establish a free and unrestricted INN for the pharmaceutical substance described below.

L'OMS est priée de bien vouloir établir une DCI à usage libre pour la substance pharmaceutique en question.

For completion by WHO/
A remplir par l'OMS

No:
Date:
Copies forwarded:

Date:

Acknowledged:

SUGGESTED NAMES (in order of preference):

DENOMINATIONS PROPOSÉES
(par ordre de préférence)

1 ..............................................
2 ..............................................
3 ..............................................

CHEMICAL NAME OR DESCRIPTION (INCLUDING STEREOCHEMICAL INFORMATION):
NOM OU DESCRIPTION CHIMIQUE (Y COMPRIS DE L'INFORMATION SUR LA STÉRÉOCHIMIE)

GRAPHIC FORMULA:
FORMULE GRAPHIQUE

MOLECULAR FORMULA:
FORMULE BRUTE

CHEMICAL ABSTRACTS SERVICE (CAS) REGISTRY NUMBER:
NUMÉRO DU REGISTRE CAS

TRADE NAME (known or contemplated):
NOM COMMERCIAL (connu ou envisagé)

ANY OTHER NAME OR CODE:
AUTRE NOM OU CODE

PRINCIPAL THERAPEUTIC USES AND POSOLOGY; PHARMACOLOGICAL ACTION:
UTILITÉ THÉRAPEUTIQUE ET POSOLOGIE; ACTION PHARMACOLOGIQUE

 

For completion by WHO/
A remplir par l'OMS


WHO 5233* PHA (9/97) -1000

PTO/TSVP

1. The process of selecting an INN should be initiated during that period of investigation when the compound is undergoing clinical study in human subjects. Please indicate the date when clinical trials began:

La procédure de sélection d'une DCI débute pendant la période d'investigation au cours de laquelle la substance fait l'objet d'études cliniques sur des sujets humains. Veuillez indiquer à quelle date ont débuté les essais cliniques:

 

2. This proposal is made on the understanding that insofar as is known, none of the suggested names is either registered or pending registration.

En présentant cette proposition, le signataire déclare qu'à sa connaissance aucune des dénominations suggérées n'a été déposée ou n'est sur le point de l'être.

 

3. The Undersigned confirms that the Chemical Abstracts Service (CAS) number is correct and permission is granted to WHO to publish it in the INN publications.

Le soussigné confirme que le numéro dans le registre du CAS est correcte et que l'OMS est autorisée à le publier dans les publications relatives aux DCIs.

 

ADDITIONAL COMMENTS:
REMARQUES

 

 


Date........................................... Signature ..........................................................................

 

to previous section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: June 25, 2014